Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome


Por: Garcia-Estrada C., Casallas-Vanegas A., Zabala-Angeles I., Gomez-Figueroa E., Rivas-Alonso V., Flores-Rivera J.

Publicada: 1 ene 2020
Resumen:
Introduction: Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome. Currently there are no treatment guidelines either for BS or NB, making the management of these patients particularly difficult. Case presentation: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy. Conclusion: This is the first report of concomitant pseudo-tumoral lesion and myelitis secondary to BS. We found rituximab treatment to be a safe and effective therapeutic option for NB supported by the radiological and clinical improvement achieved in our patient. © 2020 Elsevier B.V.

Filiaciones:
Garcia-Estrada C.:
 Multiple Sclerosis and Demyelinating Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico

Casallas-Vanegas A.:
 Multiple Sclerosis and Demyelinating Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico

Zabala-Angeles I.:
 Multiple Sclerosis and Demyelinating Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico

Gomez-Figueroa E.:
 Multiple Sclerosis and Demyelinating Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico

Rivas-Alonso V.:
 Multiple Sclerosis and Demyelinating Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico

Flores-Rivera J.:
 Multiple Sclerosis and Demyelinating Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico

 Head of Neurology Department National Institute of Neurology and Neurosurgery, Mexico City, Mexico
ISSN: 01655728
Editorial
ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 346 Número:
Páginas:
WOS Id: 000551630600016
ID de PubMed: 32619893